Friday 13 March 2026, 12pm GMT
Founded in 2013, TC BioPharm was a biotechnology company focused on the development of allogeneic gamma delta T-cell therapies for the treatment of cancer and other serious diseases. The Company’s approach centred on the development of “off-the-shelf” cell therapy products derived from healthy donors, designed to overcome the cost, scalability, and logistical limitations associated with patient-derived CAR-T therapies.
Over more than a decade of R&D and significant investment, the Company progressed multiple therapeutic candidates through pre-clinical and clinical development, including TCB-008 for the treatment of acute myeloid leukaemia. The Company’s programmes generated a substantial body of proprietary technical documentation and scientific know-how relating to the manufacture, modification, and clinical application of γδ T-cell therapies. In parallel, the Company developed proprietary cell expansion, modification, and cryopreservation methodologies, including its CryoTC platform, designed to enable scalable manufacturing and extended storage of viable therapeutic doses.
The Company developed and maintained a patent portfolio covering its core cell therapy technology and related manufacturing processes, including granted patents and pending applications across major markets such as the US, Europe, Japan, China, and Israel, with certain protections extending into the mid-2030s. Broadly, TC BioPharm’s patent portfolio protects the Company’s approach to modifying immune cells for therapeutic use, as well as the methods used to produce and apply these treatments, helping to safeguard both the underlying platform and its potential clinical applications.
The product of over $120 million of funding, including from reputable investors in the pharmaceutical industry, TC BioPharm developed a wealth of highly valuable internal technical documentation, process protocols, and know-how supporting the manufacture and application of allogeneic cell therapies, which is available to acquire.
This acquisition represents an opportunity to secure a developed γδ T-cell therapy intellectual property platform, offering a foundation from which a purchaser can conduct further research and development, integrate the technology into existing portfolios, and support broader cell therapy and advanced biologics manufacturing initiatives. For organisations active in oncology, cell and gene therapy, or immune cell engineering, the assets offer an excellent opportunity to consolidate their position in the cell therapy space.
TC BioPharm established itself as a specialised and clinically active participant within the cell and gene therapy sector.
The brand has established a strong reputation in the market for its work in clinical-stage development and engagment directly with regulatory authorities in both the US and the UK. Notably, TC BioPharm obtained FDA Investigational New Drug clearance and UK MHRA Clinical Trial Authorisation for its lead programme, representing significant regulatory milestones and reflecting the maturity and credibility of its underlying innovations. The brand was further bolstered by support and collaborations with academic and institutional partners, reinforcing its position within the broader biotechnology and immunotherapy ecosystem.
In addition to its technical and clinical progress, the TC BioPharm brand achieved visibility through the listing of its parent company on the NASDAQ Capital Market, providing international investor exposure and further establishing the brand’s profile within the global cell and gene therapy landscape.
The Company holds 13 registered trade marks protecting the “TC BioPharm” brand, together with the “CryoTC”, “OmnImmune”, “ImmuniStim”, “ImmuniCAR”, “Omnicytex”, “Stemcytex’”and “TOXFREE CAR-T” brand names.
Full details of the Company’s trade marks are available via the virtual data room.
The Company holds a patent portfolio comprising 23 granted patents and 9 pending patent applications across three patent families, providing protection around its core γδ T-cell platform technologies and associated manufacturing processes. These patents cover key aspects of immune cell modification, therapeutic application, and the methods used to produce and preserve cell therapy products.
The Company’s portfolio includes granted protection in major life sciences jurisdictions, including the US, Europe, Japan, China, and Israel, with certain patent families extending protection into the mid-2030s. Collectively, the estate reflects a structured approach to protecting both the underlying technology platform and its potential therapeutic and manufacturing applications.
Full details of the Company’s patent portfolio are available via the virtual data room.
The primary tcbiopharm.com domain name is available to acquire, alongside tcbiopharm.info.
The Company likely owns the copyright in the website content previously hosted at tcbiopharm.com, which detailed its cell therapy capabilities and associated technologies.
Rights in the Company’s LinkedIn, Twitter/X, YouTube and Facebook social media accounts are available to acquire.
The Company retains internally developed technical documentation and platform-level know-how relating to its cell therapy technologies and associated manufacturing methodologies. This includes materials connected to the CryoTC platform, process development records, technical protocols, and documented manufacturing workflows developed over the course of its research and development activities.
Together, these materials reflect the Company’s approach to immune cell modification, processing, and preservation, and provide practical insight into the technical and operational framework supporting its platform. This body of documentation may assist a purchaser in evaluating the technology, supporting further research and development, or facilitating integration into existing cell therapy or advanced biologics programmes.
Certain clinical and regulatory data packages have previously been provided to third parties. The assets available for acquisition comprise the Company’s residual intellectual property assets, including brand and digital assets, the Company’s patent portfolio and proprietary technical documentation and platform-related know-how.
No representation is made as to the scope, exclusivity, or completeness of any clinical or regulatory materials previously generated by the Company. Interested parties are advised to conduct their own enquiries and satisfy themselves as to the nature and extent of the intellectual property rights and materials available.
The deadline for offers is Friday 13 March 2026 at 12pm GMT.
All expressions of interest and bids are to be directed to Hilco in writing. A Bid Submission Form is available on request. Please contact Hilco to gain access to a virtual data room for further information on signing a confidentiality agreement.
Hilco is acting as exclusive agent to the Company and its Joint Administrators in connection with the proposed sale of some or all of the Company’s assets. The Joint Administrators act as agents of the Company and without personal liability.
All sales are made strictly on an “as is, where is” basis. Only such right, title and interest (if any) as the Company may have in the assets will be transferred to a purchaser. No warranties, guarantees, or representations (express or implied) are provided by the Company, its Joint Administrators, or Hilco in respect of the assets or any information supplied. All parties must rely on their own enquiries and due diligence. Any information provided is for convenience only and has not been independently verified.
All offers are subject to the addition of VAT at the prevailing rate, where applicable. A non-refundable deposit equal to 20% of the agreed purchase price must be paid by the successful purchaser within 48 hours of offer acceptance. Payment of the deposit grants the purchaser the exclusive right to proceed with the acquisition of the relevant assets for a limited period and on the terms agreed. A Buyer’s Premium of 10% of the final purchase price is payable by the successful purchaser in addition to the agreed purchase price, is non-negotiable and is payable at the same time and in the same manner as the purchase price and forms a condition of sale.
Legal completion must occur within five (5) business days of offer acceptance, unless otherwise agreed in writing by the Company and its Joint Administrators.
